Pfizer and Arvinas to Develop and Commercialize Estrogen Receptor Targeting Breast Cancer

The companies collaborate to develop and commercialize ARV-471, an investigational oral PROTAC (proteolysis targeting chimeras) estrogen receptor protein degrader.